Chronic ergot toxicity: A rare cause of lower extremity ischemia  by Garcia, George D. et al.
The toxic effects of ergot alkaloids have been
recognized for more 2000 years. The Book of Parsees,
written between 400 and 300 BC, warns of “. . . nox-
ious grasses that cause pregnant women to drop the
womb and die in childbed.”1 Outbreaks of epidem-
ic gangrene occurred during the Middle Ages, and
affected patients were said to be consumed by “holy
fire” because of the charcoal-like appearance and
burning pain of gangrenous limbs.2 The most effec-
tive treatment was provided at the hospitals of St
Anthony. The condition became known as “St
Anthony’s Fire.”2 In 1676, it was discovered that
Claviceps purpurea was the cause of epidemic gan-
grene. C purpurea is an ergot-producing fungus that
infects grain, most often rye.3
The major effects of ergot alkaloids are direct
smooth muscle stimulation, central sympatholytic
activity, and peripheral alpha-adrenergic blockade.4
Ergotamine decreases the vasodilation of cranial
arteries, especially the branches of the external
carotid artery that cause migraine headache.
Ergotamine may also stimulate serotonin receptors,
which causes vasoconstriction.5 Contraindications to
the use of ergot alkaloids include hepatic or renal dis-
ease, peripheral vascular disease, thrombophlebitis,
hyperthyroidism, Raynaud’s or Buerger’s disease,
and pregnancy.5
Despite the known indications and contraindica-
tions to the use of ergot-containing medications,
acute toxicity is still reported. However, there is lit-
tle reported literature on chronic lower extremity
ischemia resulting from ergot toxicity. We describe a
patient with severe lower extremity claudication
from chronic ergot toxicity who has responded well
to the discontinuance of all ergot-containing prepa-
rations and antiplatelet therapy.
CASE REPORT
A 34-year-old Hispanic woman with a 4-year history
of progressive bilateral lower extremity claudication was
seen by her primary care physician. The patient noted a
marked decrease in her walking distance over the 3
months before her evaluation, and at presentation she was
able to ambulate 50 to 75 ft before the onset of bilateral
calf pain.
Her past medical history was only remarkable for
migraine headaches, first diagnosed when she was age 13
years, for which she had taken ergot-containing medica-
tion (Cafergot and Migri Diaxadol) almost daily. She
denied any history of tobacco use, hypercholesterolemia,
hypertension, diabetes mellitus, or lower extremity trau-
ma. She was without any systemic complaints. The physi-
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cal examination was remarkable for normal upper extrem-
ity pulses and blood pressures. The lower extremity exam-
ination was remarkable for a weak left femoral pulse and
absent pedal pulses bilaterally. Ankle-brachial indices were
0.3 on the left and 0.45 on the right. She had marked ele-
vation pallor and dependent rubor of both feet. The skin
on her feet was atrophic, and she had superficial ulcers on
the great toes of both feet.
An arteriogram was obtained that showed findings
consistent with vascular ergot toxicity (Figs 1-3). All 
ergotamine-containing medications were discontinued,
and aspirin was prescribed for the patient. She has had
progressive improvement over the following 3 months,
and her superficial ulcers are healed. The patient reports
that she can walk 100 yd before the onset of pain. Her
peripheral pulse examination now shows palpable pedal
pulses and ankle-brachial indices of 0.8 bilaterally.
DISCUSSION
Ergot toxicity is seen most often in women in
their midthirties who have migraine headache.5 The
incidence of ergot intoxication is difficult to mea-
sure, but it has been estimated at less than 0.01% of
all users.4 It can occur after short-term small doses,
after excessive doses, and after therapeutic doses
over a long period of time. Most cases of ergot tox-
icity have been associated with excessive doses, but
serious extremity ischemia has been seen with as lit-
tle as 2 mg of ergotamine.5 Although the usual dose
of ergotamine is 1 mg orally or 2 mg rectally (with
100 mg of caffeine) not to exceed 10 mg in 1 week,
the absorption of ergot alkaloids is erratic, and exact
therapeutic and toxic levels have not been estab-
lished.6 There is an increased incidence of toxicity
with suppositories because absorption is greater by
means of this route.7 The clinical signs of ergotism
do not correlate with blood ergotamine levels
because toxicity can occur even with undetectable
blood levels.6
Three classes of side effects can occur with ergot
toxicity: neurologic side effects, including headache,
vertigo, psychosis, convulsions, and coma; alimentary
side effects, including nausea, vomiting, diarrhea, and
cramping abdominal pain; and finally, vascular side
effects, including vasospasm and, rarely, thrombosis.8
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Fig 1. Pelvic arteriogram showing marked vasospasm and
extensive collaterals. Note the narrow left external iliac
artery.
Fig 2. Extensive vasospasm of the right superficial femoral
artery.
Fig 3. Marked vasospasm of the left superficial femoral
artery.
The predominant vascular toxicity occurs in the
extremities, with 60% to 70% of cases affecting the
lower limbs.2 However, cases of vasospasm in the
aorta, renal, carotid, digital, mesenteric, retinal, and
coronary arteries have been reported, as well as uter-
ine cramping and spontaneous abortion.5 The vas-
cular insufficiency of ergotism results from spasm
and is characterized in the extremity by pallor, cool-
ness, numbness, and intermittent claudication pro-
gressing to pain at rest. If ergot use continues, the
affected limb may develop dry gangrene and, less
commonly, suppurative gangrene and sepsis.4
There are three arteriographic findings that can
be seen in ergotism: a generalized intense arterial
spasm, formation of collateral vessels, and throm-
boses.8 Spasm most often begins in the superficial
femoral artery and becomes more severe distally
with smooth, tapered, “threadlike narrowings,” fol-
lowed by abrupt severe spasm causing distal occlu-
sion.5 In chronic toxicity, collateral vessels form.
Treatment for ergot toxicity begins with the dis-
continuance of the drug, of caffeine, and of ciga-
rettes. In some cases, resolution can be expected in
as soon as 10 days.9 With prolonged use, however,
reversal of symptoms may take several months.10 In
cases of acute ergot toxicity, other treatment options
have met with varied levels of success, and none has
emerged as a treatment of choice. Dagher et al7
describe a patient successfully treated with the calci-
um channel blocker nifedipine. Dierckx et al11 rec-
ommended continuous infusion of the direct acting
vasodilator sodium nitroprusside in a patient with a
3-day history of left foot ischemia. Although nitro-
prusside has proved to be effective in acute cases, it
has not been proved in chronic toxicity.10 A reason-
able alternative to continuous infusion, suggested by
Wells et al5 in a patient with bilateral rest pain, is oral
prazosin hydrochloride, which, by means of alpha-
adrenergic blockade, reduces vascular tone, similar
to nitroprusside. This treatment is recommended
only when gangrene is imminent or vascular access is
difficult.5 Edwards et al12 had success with continu-
ous infusion of prostacyclin (prostaglandin I2) in the
treatment of a patient with 7 days of increasing pain
and coolness in both legs. Both prostacyclin and
prostaglandin E2 cause vasodilatation of arterial and
venous beds and are potent antiplatelet agents. For
severe, acute, ergot-induced vasospasm that fails to
respond to conservative treatment, Baader et al13
used intra-arterial balloon dilation in a patient with
3 weeks of bilateral hand ischemia. This was success-
ful, presumably because of disruption of arterial
smooth muscle, which prevented vasoconstriction.
CONCLUSION
We have presented the case of a 34-year-old
woman with a 20-year history of ergot use that has
resulted in chronic arterial insufficiency. No other
case in the literature has documented symptoms of
this duration. The cornerstone of therapy in ergot
toxicity is to discontinue the use of caffeine, ciga-
rettes, and all ergot-containing medications. We rec-
ommend a conservative approach consisting of
observation, antiplatelet agents, and the discontinu-
ance of ergots. If symptoms progress to rest pain or
gangrene, surgical treatment should be considered.
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